Nicotinamide Riboside for Diabetic Neuropathy

Sponsor: University of Maryland, Baltimore
Collaborator: US Department of Veterans Affairs

Purpose

To investigate the use of NR as a potential treatment for diabetic neuropathy in subjects with type 2 diabetes mellitus or impaired glucose tolerance over a 6 month period. Endpoints will include intraepidermal nerve fiver density, clinical and electrophysiological outcomes, quality of life and biochemical measures.

Study Design

Randomized, double blind, parallel assignment

Dose

2x 250mg capsules 2x/day (1000mg total)

Length of Intervention

6 months

Intrinsic Capacity

Sensory

Status

Recruiting

Condition or Disease 

Diabetic Neuropathy Peripheral

Timeline estimations sourced on clinicaltrials.gov. All timing subject to change.

Clinical Studies, Sensory, RecruitingANAD Staff